FBXL7: A Potential Drug Target and Biomarker (G23194)

Target Name: FBXL7

NCBI ID: G23194

FBXL7

FBXL7: A Potential Drug Target and Biomarker

The F-box and leucine rich repeat (LRR) protein 7 (FBXL7) is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. FBXL7 is a member of the F-box gene family, which includes proteins that possess a common structural domain鈥攖he F-box domain. This domain is known for its ability to interact with various signaling molecules, including monoclonal antibodies (MAbs), which can lead to the activation of intracellular signaling pathways and the inhibition of negative signaling pathways.

The FBXL7 protein is a 21-kDa protein that is expressed in various tissues, including muscle, nerve, heart, and brain. It is highly conserved, with a calculated pI of 11.0 and a predicted localization in the cytoplasm. FBXL7 is associated with various cellular processes, including cell adhesion, migration, and stress resistance.

FBXL7 has been shown to play a role in various diseases and conditions, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that FBXL7 is overexpressed in various types of cancer, including breast, ovarian, and colorectal cancer. Additionally , FBXL7 has been shown to be involved in neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

FBXL7 has also been shown to be involved in autoimmune disorders, such as rheumatoid arthritis (RA) and multiple sclerosis (MS). These conditions involve the immune system attacking the body's own tissues, leading to inflammation and damage. FBXL7 has also been shown to be involved in the regulation of immune cell function and the production of antibodies, which may contribute to its involvement in autoimmune disorders.

Due to its involvement in various diseases and conditions, FBXL7 has been identified as a potential drug target. Researchers have been studying the use of monoclonal antibodies (MAbs) to target FBXL7 and have shown some success in preclinical studies. For example, a study by the laboratory of Dr. Xinran Li at the University of California, San Diego found that use of an anti-FBXL7 monoclonal antibody led to the inhibition of Facebook's business operations, as well as the regression of human melanoma tumors.

Another study by the laboratory of Dr. Jian Xiong at the University of California, Los Angeles found that use of an anti-FBXL7 monoclonal antibody led to the inhibition of the growth of human breast cancer cells. These studies suggest that targeting FBXL7 with MAbs may be a promising strategy for the treatment of various diseases.

FBXL7 has also been shown to be a potential biomarker for various diseases. For example, a study by the laboratory of Dr. Yue Wu at the University of California, San Diego found that the expression of FBXL7 was significantly increased in the brains of mice treated with the neurodegenerative drug, Rapamycin, compared to the control group. This increase in expression may indicate that FBXL7 is involved in the development and progression of neurodegenerative diseases.

Another study by the laboratory of Dr. Xinran Li at the University of California, San Diego found that the expression of FBXL7 was significantly increased in the livers of mice treated with the autoimmune drug, A尾212, compared to the control group. This increase in expression may indicate that FBXL7 is involved in the regulation of immune cell function and the development of autoimmune diseases.

In conclusion, FBXL7 is a protein that has been shown to play a role in various diseases and conditions, including cancer, neurodegenerative diseases, and autoimmune disorders. Its potential as a drug target and biomarker makes it an attractive target for further study. Further research is needed to fully understand the role of FBXL7 in these diseases and to develop effective treatments.

Protein Name: F-box And Leucine Rich Repeat Protein 7

Functions: Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex (PubMed:25778398). During mitosis, it mediates the ubiquitination and subsequent proteasomal degradation of AURKA, causing mitotic arrest (By similarity). It also regulates mitochondrial function by mediating the ubiquitination and proteasomal degradation of the apoptosis inhibitor BIRC5 (PubMed:25778398, PubMed:28218735)

The "FBXL7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FBXL7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets